EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)

Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Yuqin Ding, Wenju Mo, Xiaohong Xie, Ouchen Wang, Xiangming He, Shuai Zhao, Xidong Gu, Chenlu Liang, Chengdong Qin, Kaijing Ding, Hongjian Yang, Xiaowen Ding

Oncology Research and Treatment · 2023

DOI: 10.1159/000531492 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Oncology Research and Treatment, 2023. Verfasst von Yuqin Ding und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Zhejiang Cancer Hospital, Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This multicenter, randomized, double-blind, placebo-controlled phase 2 trial compared the efficacy, and safety of adding pyrotinib to trastuzumab, docetaxel, and carboplatin versus placebo, trastuzumab, docetaxel, and carboplatin in Chinese patients with human epidermal receptor 2 (HER2)-positive early or locally advanced breast cancer (ClinicalTrials.gov identifier: NCT03756064).

Methods

Sixty-nine women with HER2-positive early (T1-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0) were recruited from October 1, 2019, to June 1, 2021. Before surgery, patients received 6 cycles of orally pyrotinib (400 mg once per day), trastuzumab (8-mg/kg loading dose and 6-mg/kg maintenance doses), docetaxel (75 mg/m2), and carboplatin (AUC = 6 mg/mL·min) or orally placebo, trastuzumab, and docetaxel, and carboplatin every 3 weeks. The primary end point was independent review committee-assessed total pathologic complete response rate. The 2-sided Cochran-Mantel-Haenszel test, stratified by age, hormone receptor status, tumor stage, nodal status, cTNM stage, and Ki-67 level was used to compare rates between treatment groups.

Results

In total, 69 female patients were randomized (pyrotinib, 36; and placebo, 33; median age, 53 [31–69] years). In the intention-to-treat population, total pathologic complete response rates were 65.5% (19/29) in the pyrotinib group and 33.3% (10/30) in the placebo group (difference, 32.2%, p = 0.013). Diarrhea was been reported in 86.1% of patients (31/36) in the pyrotinib group as the most common adverse events (AEs) and 15.2% of patients (5/33) in the placebo group. But no grade 4 or 5 AEs were reported.

Conclusion

Treatment with pyrotinib, trastuzumab, docetaxel, and carboplatin resulted in a statistically significant improvement in the total pathologic complete response rate versus placebo, trastuzumab, docetaxel, and carboplatin for the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer in Chinese patients. Safety data were in line with the known pyrotinib safety profile and generally comparable between treatment groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleMiddle AgedTrastuzumabDocetaxelCarboplatinNeoadjuvant TherapyErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeAcrylamidesAminoquinolines

Stichwörter der Autor:innen

Breast cancerHuman epidermal receptor 2Neoadjuvant therapyPhase II trialPyrotinibTrastuzumabTyrosine kinase inhibitor

Substanzen

TrastuzumabDocetaxelCarboplatinErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedpyrotinibAcrylamidesAminoquinolines

Autor:innen und Institutionen

  • Department of Breast Surgery, Zhejiang Cancer Hospital, Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
  • Department of Breast Surgery, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, China.
  • Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Child psychology, Affiliated Mental Health Center and Hangzhou Seventh People's Hospital University School of Medicine, Hangzhou, China.

Zitieren

APA

Ding, Y., Mo, W., Xie, X., Wang, O., He, X., Zhao, S., Gu, X., Liang, C., Qin, C., Ding, K., Yang, H., & Ding, X. (2023). Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Oncology Research and Treatment. https://doi.org/10.1159/000531492

Vancouver

Ding Y, Mo W, Xie X, Wang O, He X, Zhao S, et al. Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Oncology Research and Treatment. 2023. doi:10.1159/000531492

BibTeX
@article{Ding2023,
  author = {Ding, Yuqin and Mo, Wenju and Xie, Xiaohong and Wang, Ouchen and He, Xiangming and Zhao, Shuai and Gu, Xidong and Liang, Chenlu and Qin, Chengdong and Ding, Kaijing and Yang, Hongjian and Ding, Xiaowen},
  title = {Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial},
  journal = {Oncology Research and Treatment},
  year = {2023},
  doi = {10.1159/000531492}
}
Kostenlos starten →